Sort
64,565 grants matching “drug discovery”
HIV-1 RNase H as a Therapeutic Target
$647,495Stuart F. J. Le Grice · Division Of Basic Sciences - Nci · ZIA · FY2012 · CA
Boston University Clinical and Translational Science Institute
$647,476David Tobin Felson · Boston University Medical Campus · KL2 · FY2018 · TR
Epidemiologic Studies
$647,476Stephen B Gruber · University Of Michigan At Ann Arbor · U19 · FY2010 · CA
Boston University Clinical and Translational Science Institute
$647,476David Tobin Felson · Boston University Medical Campus · KL2 · FY2016 · TR
Endosomal Platforms for Signaling Pain
$647,474Nigel W Bunnett · New York University · R01 · FY2024 · NS
Bronchiolitis Obliterans: Discovery and Therapy
$647,464Corey S Cutler · Dana-Farber Cancer Inst · P01 · FY2025 · HL
Discovery of Novel Inhibitors Targeting trans-Golgi Network Acidification in Pancreatic Cancer
$647,398Cosimo Commisso · Sanford Burnham Prebys Medical Discovery Institute · R01 · FY2023 · CA
Validation of Occupancy Images from PET Data. A Novel Endpoint for Drug Discovery
$647,324Evan D Morris · Yale University · R01 · FY2022 · EB
Cryopreservation and nanowarming enables whole liver banking for transplantation, cell therapy and biomedical research
$647,312Erik Brian Finger · University Of Minnesota · R01 · FY2024 · DK
Human Cytomegalovirus Nuclear Egress: Molecular Mechanisms and Drug Targeting
$647,245Donald M Coen · Harvard Medical School · R01 · FY2014 · AI
Curaxin-137, A New Lead for Anti-Trypanosome Drug Discovery - Resubmission - 1
$647,208Kojo Mensa-Wilmot · University Of Georgia · R01 · FY2019 · AI
A Reduced Complexity Cross in BALB/c substrains to identify the genetic basis of oxycodone dependence phenotypes
$647,133Camron D Bryant · Boston University Medical Campus · U01 · FY2021 · DA
Discovery of synthetic and endogenous ligands for orphan GPCR GPR156
$646,743Cesare Orlandi · University Of Rochester · R01 · FY2025 · DC
Novel Sample Introduction Methodologies for Molecular Rotational Resonance (MRR) Spectroscopy
$646,725Voislav Blagojevic · Brightspec, Inc. · R44 · FY2024 · GM
Development of P2Y Receptor Ligands
$646,531Kenneth Alan Jacobson · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2025 · DK
Hemopexin as an Early Biomarker of Anthracycline Cardiac Toxicity
$646,527Aarti Asnani · Beth Israel Deaconess Medical Center · R01 · FY2025 · HL
ANTICANCER DRUGS ACTIVE AGAINST CELL CYCLE AND SIGNAL PA
$646,525University Of Arizona · U19 · FY2001 · CA
Drug Screening with a Biofrabricated 3-D Immunocompetent Skin Model for Drug Discovery in Psoriatic Disease
$646,512Angela M Christiano · Columbia University Health Sciences · U18 · FY2020 · TR
Development of Dual-Action Nanoparticle-Loaded Microparticles for Osteoarthritis Treatment
$646,506Zhiliang Cheng · University Of Pennsylvania · R01 · FY2025 · AR
Reversible male contraception by inhibition of serine/threonine kinase 33
$646,413Martin M Matzuk · Baylor College Of Medicine · R01 · FY2024 · HD
Biological Insights from Genetic Investigation of ANthropometric Traits (GIANT) Across the Allelic Spectrum
$646,364Joel N Hirschhorn · Boston Children'S Hospital · R01 · FY2025 · DK
Mechanism Based Inhibition of M Tuberculosis Enzymes
$646,225John S Blanchard · Albert Einstein College Of Medicine · R01 · FY2012 · AI
NAAA Inhibitors as Anti-inflammatory Agents, Phase II
$646,219Shakiru Olajire Alapafuja · Makscientific, Llc · R44 · FY2017 · DK
NAAA Inhibitors as Anti-inflammatory Agents, Phase II
$646,219Shakiru Olajire Alapafuja · Makscientific, Llc · R44 · FY2016 · DK
High content screening of Mycobacterium tuberculosis
$646,203Tanya Parish · Access To Advanced Health Institute · R01 · FY2017 · AI